Specific use-results survey to evaluate the safety and outcome of Pivlaz use in patients after aneurysmal subarachnoid hemorrhage treatment
Latest Information Update: 08 Jul 2022
At a glance
- Drugs Clazosentan (Primary)
- Indications Cerebral vasospasm
- Focus Adverse reactions
- Sponsors Idorsia Pharmaceuticals
Most Recent Events
- 08 Jul 2022 New trial record